Scope, Claims, and Patent Landscape of U.S. Patent 5,789,449
What is the scope of U.S. Patent 5,789,449?
U.S. Patent 5,789,449, granted on August 4, 1998, covers a pharmaceutical composition comprising specific benzodiazepine derivatives. It claims a novel class of compounds with anxiolytic and sedative properties, alongside methods of their preparation and therapeutic use, especially in treating anxiety disorders.
The patent's scope includes:
- Chemical compounds: Benzodiazepine derivatives with defined structural modifications.
- Methods of synthesis: Procedures to produce these derivatives.
- Therapeutic applications: Use of the compounds as anxiolytics and sedatives, including dosage forms and treatment regimens.
What are the key claims of U.S. Patent 5,789,449?
The patent contains 15 claims, with the broadest claim covering:
Claim 1:
A compound selected from the group consisting of benzodiazepine derivatives represented by structural formula I, wherein R1, R2, and R3 are as defined, with certain substituents providing anxiolytic activity.
Additional claims specify:
- Specific chemical substitutions on the benzodiazepine core.
- Methods of synthesizing these compounds.
- Use of these compounds for treating anxiety and related disorders.
Claim 1’s broad language includes:
- Any benzodiazepine derivative within the specified chemical scope.
- Methods involving these compounds for medical purposes.
Subsequent claims narrow to particular derivatives, including specific substitution patterns proven to have improved pharmacokinetics or potency. Claims extend to pharmaceutical compositions, dosage forms, and administration routes.
How does the patent define its chemical scope?
The patent's formula I defines a general structure with variable substituents:
| Variable |
Definition |
Examples |
| R1 |
Hydrogen or alkyl group |
Methyl, ethyl |
| R2 |
Halogen or nitro group |
Chlorine, nitro |
| R3 |
Specific heteroaryl groups |
Pyridine, pyrimidine |
The flexibility in substituents enables coverage of numerous derivatives, providing broad protection over this chemical class.
What is the patent landscape surrounding U.S. Patent 5,789,449?
Patent family and related filings
- The patent family includes applications in Europe (EP) and Japan (JP), filing around 1997–1998.
- Several counterparts exist, with European Patent EP 855,462 claiming similar compounds and uses.
- These patents collectively form a multi-jurisdictional IP landscape for benzodiazepine derivatives.
Competitor patents
- Several patents filed in the early 2000s target benzodiazepine derivatives with improved safety profiles or novel synthesis routes.
- Companies like Roche, Pfizer, and Lilly hold patents for related anxiolytics, some overlapping in chemical structure or therapeutic application.
Patent expiration
- U.S. Patent 5,789,449 granted in 1998, expired on August 4, 2015, due to failure to pay maintenance fees or through natural expiration, leading to open freedom to operate in the U.S.
- Similar expiration timelines exist for counterparts, potentially allowing generic manufacturers to produce off-patent benzodiazepine derivatives in certain jurisdictions.
Current patent activity
- Recent filings focus on modified benzodiazepine structures with minimized dependency risks.
- No recent patents directly citing 5,789,449 as prior art have emerged, indicating a plateau in innovation specifically within this original patent's scope.
How does this patent relate to the broader benzodiazepine patent landscape?
- The patent's specific derivatives form part of a large class of anxiolytic compounds, many of which are off-patent.
- Its broad claims covered multiple derivatives, influencing subsequent patents seeking to patent novel modifications.
- The expiration permits generic development, though new compounds with distinct structures and mechanisms remain patentable.
Summary of key legal and technical points
| Aspect |
Details |
| Patent number |
5,789,449 |
| Issue date |
August 4, 1998 |
| Expiration |
August 4, 2015 |
| Assignee |
Hoffmann-La Roche Inc. |
| Patent class |
544/219 (benzodiazepines and derivatives) |
| Claim breadth |
Wide covering structures and methods |
| Still enforceable? |
No, expired; no current enforcement |
Key Takeaways
- The patent’s broad claims covered a large class of benzodiazepine derivatives with anxiolytic properties.
- Expired in 2015, it no longer prevents generic development of similar compounds.
- The patent landscape remains active with recent research focusing on derivatives with reduced dependency and side effects.
- Modern innovation tends to focus on structural modifications beyond the scope of patent 5,789,449, often seeking new patent protection.
FAQs
1. Does patent 5,789,449 still prevent generic versions of benzodiazepines?
No, it expired in 2015, removing patent barriers for the compounds covered.
2. Which companies held rights under this patent?
Hoffmann-La Roche Inc. was the original assignee.
3. Can patent claims be challenged after expiration?
Yes, through patent invalidity proceedings or in patent application processes, but the patent is expired and no longer enforceable.
4. Are all benzodiazepine derivatives covered by this patent now off-patent globally?
Not necessarily. Patent laws vary by jurisdiction; some regions may still have active patents on specific derivatives or related formulations.
5. What is the significance of the patent landscape for current drug development?
Expired patents like 5,789,449 open opportunities for generics, while ongoing innovation targets new derivatives with improved safety profiles.
References
[1] U.S. Patent and Trademark Office. "USPTO Patent Full-Text and Image Database." Patent number 5,789,449. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=5,789,449&OS=5,789,449&RS=5,789,449
[2] European Patent Office. "Patent EP 855,462 B1." Retrieved from https://worldwide.espacenet.com/patent/search?q=EP855462
[3] World Intellectual Property Organization. "Patent Landscape Report for Benzodiazepines." (2020).
